Brenna Kenney
Family · Virginia Beach, VANPI 1083103360
Payments from drug & device makers
Across 157 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$829
- Amgen$468
- AbbVie$464
- Lilly USA, LLC$330
- Novo Nordisk$276
- Exact Sciences$264
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,650100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $829 |
| Amgen | 17 | $468 |
| AbbVie | 27 | $464 |
| Lilly USA, LLC | 7 | $330 |
| Novo Nordisk | 18 | $276 |
| Exact Sciences | 13 | $264 |
| Dexcom, Inc. | 9 | $244 |
| Pfizer | 7 | $156 |
| Bayer | 8 | $144 |
| Eisai Inc. | 1 | $125 |
| Abbott | 4 | $93 |
| GSK | 5 | $86 |
| Merck | 2 | $32 |
| Boehringer Ingelheim | 2 | $25 |
| Amarin Pharma, Inc. | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Neurelis, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,650 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $97,984 |
| EliquisApixaban | 60 | $50,306 |
| JardianceEmpagliflozin | 38 | $35,325 |
| JanuviaSitagliptin Phosphate | 22 | $31,314 |
| TradjentaLinagliptin | 34 | $27,540 |
| XareltoRivaroxaban | 13 | $22,280 |
| TrulicityDulaglutide | 19 | $19,007 |
| RybelsusSemaglutide | 11 | $14,847 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $9,911 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $4,682 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $3,699 |
| Lurasidone Hcl | 11 | $2,721 |
| VascepaIcosapent Ethyl | 12 | $2,092 |
| ValacyclovirValacyclovir Hcl | 24 | $2,086 |
| Atorvastatin Calcium | 227 | $1,953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $276 | $112,83173 claims |
| Boehringer IngelheimJardiance, Tradjenta | $25 | $62,86572 claims |
| PfizerEliquis | $156 | $50,30660 claims |
| MerckJanuvia | $32 | $31,31422 claims |
| Johnson & JohnsonXarelto | $15 | $22,28013 claims |
| Lilly USA, LLCTrulicity | $330 | $19,00719 claims |
| GSKTrelegy Ellipta | $86 | $9,91113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,332 family providers in Virginia.
Other family in Virginia Beach
- Andrea CottonVirginia Beach$696K
- Rachel KingVirginia Beach$51K
- Laura JacksonVirginia Beach$22K
- Kim PhamVirginia Beach$13K
- Joseph BowmanVirginia Beach$11K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.